New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.
Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.
HDC-ASCT improves outcomes vs immunochemotherapy in newly diagnosed primary CNS lymphoma, a phase 3 study suggests.
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.